Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

Recent GU Developments and Their Clinical Implications

Insights from 2024 ASCO® GU Annual Meeting

T. Powles, B. Rini

Treatment (De)Intensification in RCC

International Urology Cancer Summit - IUCS

S. Kumar Pal

Year in Review: Cutting Edge Advances in Kidney Cancer - Imaging and…

Ketan Badani

Hyperprogression in Cancer Treated With Immunotherapy

Northwestern Medicine Oncology and Hematology

Y. Chae

Year in Review 2024 - Renal Cell Carcinoma

Oncology 2024 Year in Review

N. Mar

ASCO® 2024 Summary: "Current Updates in RCC - Clinical Implications …

2024 ASCO® Annual Meeting Insights Hub

K. Mittal

No Role to Continue ICI Beyond Progression: CONTACT-03 & TiNivo-2 Ph…

Dana-Farber Cancer Institute

B. McGregor

The Surgeon's Management of Advanced Kidney Cancer

Daniel Shapiro

SIU 2024 Insights: Partial Nephrectomy - Open, Laparoscopic or Robot…

Miguel Ramos

Updating Treatment Sequencing for mRCC

International Urology Cancer Summit - IUCS

N. Vasudev

ESMO 2024 Summary: Important GU Trials - ETER100 (RCC), TACITO (mRCC…

2024 ESMO Annual Meeting Insights Hub

C. Porta

Best of Bladder Cancer and RCC From ESMO 2023 and GU ASCO 2024

Total Health

M. Reimers

ASCO® 2024 Summary: "Bladder and RCC Highlights"

2024 ASCO® Annual Meeting Insights Hub

K. Tawagi, N. Reizine

ESMO 2024 Insights: TACITO Trial - Fecal Microbiota Transplantation …

2024 ESMO Annual Meeting Insights Hub

C. Ciccarese

Year in Review 2024 - 1L Combination Therapies for aRCC

Oncology 2024 Year in Review

Y. Zakharia

Review of Kidney Cancer Updates From ESMO 2024

The View on GU | with Lalani & Wallis

A. A. Lalani, C. Wallis

ESMO 2024 Insights: SC vs. IV Nivolumab in Advanced/Metastatic RCC -…

2024 ESMO Annual Meeting Insights Hub

L. Albiges

ESMO 2024 Insights: Final Analysis of the Phase 3 LITESPARK-005 Stud…

2024 ESMO Annual Meeting Insights Hub

B. Rini

Unmet Needs in Advanced RCC Beyond 2L

Pablo Maroto